ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase ...
“American fascism would . . . be correspondingly democratic in the American fashion.” — Bertolt Brecht, Journals At the end of last year, Donald Trump deployed more than two thousand Immigration and ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type ...
Johnson & Johnson today announced findings from the first network meta-analysis (NMA) comparing CAPLYTA® (lumateperone) to FDA-approved atypical antipsychotics for add-on treatment of major depressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results